23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
23andMe Lays Off 40% of Staff, Shuts Drug Development Business Read More »
23andMe Lays Off 40% of Staff, Shuts Drug Development Business Read More »
Chinese Car Sales Rise Sharply on Subsidies, Robust Demand Read More »
Sony’s Profit Jumps on Strength in Game, Image-Sensor Businesses Read More »